Sunday, June 01, 2008


Pharma Expansion

More global acquisitions by pharma companies in India.
Zydus Cadilla
Zydus Cadila acquired Laboratorios Combix of Spain for an undisclosed amount.

The acquisition would facilitate Zydus to enter into the generics market that is estimated at $1.7 billion and growing at 21%, as against the total pharma market at 6% (in 2007), says a company statement. Spain is the fifth-largest pharmaceuticals market in the world.

The acquisition of Combix lets Zydus start its business and leverage strength in product development and cost-competitive supply chain. "...This acquisition offers us an opportunity to consolidate our presence as a generics company and global healthcare provider. The Spanish generics market is forecast to grow rapidly and we are pleased to participate in this growth," Zydus Cadila CMD Pankaj R Patel said.

Laboratorios Combix has a portfolio covering 17 molecules and a range of products pending launch or in the pipeline.

Jubilant Organosys
Jubilant Organosys has acquired Draxis Health of Canada for $255 million. Draxis Health provides products in three categories: sterile products, non-sterile products and radiopharmaceuticals. Sterile products include liquid and freeze-dried (lyophilized) injectables plus sterile ointments and creams. Non-sterile products are produced as solid oral and semi-solid dosage forms. Radiopharmaceuticals are used for both therapeutic and diagnostic molecular imaging applications. Pharmaceutical contract manufacturing services are provided through the Draxis Pharma division.

The latest deal takes Jubilant into the top five sterile manufacturing concerns in North America, according to Jubilant's chairman and managing director, Shyam Bhartia. Draxis also adds to Jubilant's capacity in non-sterile products, such as solid oral and semi-solid dosage forms, which boasts a long-term contract with healthcare giant Johnson & Johnson.

Jubilant Organosys has a turnover of $250 million and has over 2300 employees. It is the largest custom research and manufacturing services (CRAMS) company and a leading manufacturer of active pharmaceutical ingredients in India.

In 2005 it acquired Target Research Associates, a contract research firm in the US. Jubilant also has a stake in Belgium's Pharmaceutical Services Inc and US generic company Trigen Laboratories. Last November the company said it had set up a $100 million fund for acquisitions: the current deal is for around that amount in cash, with $155 million raised in debt

Also see:

Pharma Acquisitions

Links to this post:

Create a Link

<< Home

This page is powered by Blogger. Isn't yours?